CONCLUSION
In the current study, we
identified FGFR3 gene amplification (10 copies) in a patient with
gastric adenocarcinoma. Targeting FGFR3 amplification with Pazopanib in
combination with Gemcitabine and Pemetrexed yielded significant durable
response. These results suggest that ETA-guided combination regimens of
targeted and cytotoxic agents targeting FGFR3 is an efficient treatment
strategy in FGFR3 amplified gastric cancer patients.
ACKNOWLEDGEMENTS
The authors acknowledge the patient and his family for consenting to
publication of the deidentified case details. The contributions of staff
from HCG Manavata Cancer centre as well as of Datar Cancer Genetics are
acknowledged.